```html

Quinazoline Rash

What is Quinazoline Rash?

A quinazoline rash is a skin eruption that occurs as an adverse reaction to medications containing a quinazoline core, most commonly the topical vasodilators brimonidine and oxymetazoline. These drugs are frequently used to treat ocular conditions such as glaucoma or to reduce nasal congestion. When the skin becomes sensitized, patients may develop redness, itching, papules, or even a more widespread eczema‑like eruption at the site of application or on distant skin areas. The rash is typically a type IV hypersensitivity reaction, meaning it is mediated by T‑cells rather than immediate IgE antibodies.

Although the term “quinazoline rash” is not found in major dermatology textbooks, it is widely used in pharmacovigilance reports and clinical case series to describe this specific drug‑induced dermatitis. The condition is usually self‑limiting once the offending agent is stopped, but severe cases can progress to extensive eczema, secondary infection, or systemic symptoms.

Common Causes

Quinazoline rash most often follows exposure to the following agents or situations:

• Brimonidine tartrate 0.15% ophthalmic solution – used for open‑angle glaucoma.
• Oxymetazoline nasal spray or eye drops – over‑the‑counter decongestant.
• Topical beta‑blocker–quinazoline combinations (e.g., timolol‑brimonidine).
• Compounded quinazoline preparations – occasionally used in research settings.
• Cross‑reactivity with other quinazoline derivatives – such as certain anti‑cancer agents (e.g., gefitinib) that share the core structure.
• Concurrent use of photosensitizing agents – sun exposure can amplify the rash.
• Improper application techniques – excessive dosing or contamination of the skin.
• Pre‑existing skin conditions – eczema, atopic dermatitis, or psoriasis may predispose to a reaction.
• Genetic predisposition – certain HLA types (e.g., HLA‑B*57:01) have been linked to drug‑induced skin reactions, though data for quinazolines are limited.
• Repeated exposure – cumulative sensitization over weeks to months.

Associated Symptoms

Patients with a quinazoline rash often notice additional signs that help differentiate it from simple irritation:

• Pruritus – itching is the most common accompanying symptom.
• Burning or stinging sensation at the application site.
• Papular or vesicular lesions – small raised bumps, sometimes filled with fluid.
• Erythema – well‑demarcated redness spreading beyond the contact area.
• Scaling or crusting after a few days.
• Swelling (angio‑edema) – especially with facial involvement.
• Systemic symptoms – low‑grade fever, malaise, or lymphadenopathy in severe cases.
• Secondary infection – indicated by increased pain, pus, or foul odor.

When to See a Doctor

Most drug‑induced rashes improve after discontinuation of the suspect medication, but you should contact a healthcare professional promptly if you notice any of the following:

• Rash that spreads rapidly or covers more than 10 % of your body surface.
• Severe itching or pain that interferes with sleep or daily activities.
• Blisters, bullae, or skin that peels off (suggesting Stevens‑Johnson syndrome or toxic epidermal necrolysis).
• Swelling of the lips, tongue, or throat (possible anaphylaxis).
• Fever >38 °C (100.4 °F) accompanying the rash.
• Signs of infection – increasing redness, warmth, pus, or a foul smell.
• Visual changes, eye pain, or worsening of glaucoma symptoms after starting an eye drop.
• Any concern that the rash might be related to a medication you cannot safely stop without a physician’s guidance.

Diagnosis

Diagnosing a quinazoline rash is primarily clinical, but several steps help confirm the cause and rule out other conditions:

1. Detailed History

• Medication list (prescription, OTC, herbal, and compounded).
• Start date, dosage, and application technique of the suspected drug.
• Previous drug reactions or known allergies.
• Exposure to sunlight, heat, or other irritants.

2. Physical Examination

• Pattern, distribution, and morphology of lesions.
• Presence of vesicles, pustules, or target lesions.
• Assessment of mucosal involvement (oral, ocular).

3. Laboratory & Diagnostic Tests (if needed)

• Patch testing – performed by an allergist or dermatologist to confirm a delayed‑type hypersensitivity to quinazoline.
• Skin biopsy – helps differentiate from psoriasis, lupus, or contact dermatitis.
• Complete blood count (CBC) – may reveal eosinophilia in drug reactions.
• Serum IgE – usually normal, helping distinguish from immediate‑type allergy.
• Culture of any secondary infection.

4. Differential Diagnosis

Conditions that can mimic a quinazoline rash include:

• Contact dermatitis from other topical agents.
• Atopic or seborrheic eczema.
• Rosacea (particularly with ocular involvement).
• Herpes zoster or herpes simplex infections.
• Drug‑reaction with eosinophilia and systemic symptoms (DRESS).

Treatment Options

Treatment focuses on removing the offending agent, alleviating symptoms, and preventing complications.

1. Discontinuation of the Suspect Drug

The most effective step is to stop the quinazoline‑containing medication. If the drug is essential (e.g., for glaucoma), the prescribing physician may substitute an alternative class such as prostaglandin analogs, carbonic anhydrase inhibitors, or selective α‑agonists without a quinazoline backbone.

2. Topical Therapies

• Low‑potency corticosteroids (e.g., hydrocortisone 1 %) for mild erythema and itching.
• Medium‑potency steroids (e.g., triamcinolone 0.1 %) for moderate inflammation.
• Calcineurin inhibitors (tacrolimus 0.03 % or pimecrolimus 1 %) – useful on thin skin (eyelids) where steroids may cause atrophy.
• Barrier creams (zinc oxide, petrolatum) to protect irritated skin.

3. Systemic Therapies (for extensive or severe reactions)

• Oral antihistamines (cetirizine, loratadine) to control pruritus.
• Short courses of systemic corticosteroids (prednisone 0.5 mg/kg/day) for widespread dermatitis.
• In cases with secondary infection, antibiotics based on culture results.

4. Symptomatic Home Care

• Cool compresses (10‑15 minutes, 3–4 times daily) to soothe burning.
• Oatmeal or colloidal‑silver bath additives to reduce itching.
• Avoid scratching; keep nails short to limit skin damage.
• Use hypoallergenic, fragrance‑free soaps and moisturizers.

5. Follow‑up

Re‑evaluate after 5–7 days. Persistent or worsening rash warrants dermatology referral.

Prevention Tips

While not all drug reactions are predictable, these strategies markedly lower the risk of developing a quinazoline rash:

• Review medication history with your provider before starting a new eye drop or nasal spray.
• Ask whether a non‑quinazoline alternative exists, especially if you have a known drug allergy.
• Apply the medication precisely as prescribed—no extra drops or sprays.
• Wash hands thoroughly before and after application to avoid accidental skin contact.
• Never share ophthalmic or nasal preparations with others.
• Monitor the skin for any redness or itching for the first 48 hours after starting therapy.
• If you have a history of eczema or atopic dermatitis, discuss prophylactic skin barrier measures with your clinician.
• Protect the treated area from excessive sunlight; use sunscreen (SPF 30+) on surrounding skin.
• Keep a written record of drug reactions to share with all future healthcare providers.

Emergency Warning Signs

Key Take‑aways

Quinazoline rash is an uncommon but recognizable drug‑induced dermatitis linked to certain glaucoma and nasal decongestant medications. Early identification, prompt discontinuation of the causative agent, and appropriate topical or systemic therapy lead to swift recovery for the majority of patients. However, because the rash can evolve into severe skin or systemic reactions, vigilance for warning signs and timely medical evaluation are essential.

References:

• Mayo Clinic. “Drug rash and allergy.” Updated 2023. https://www.mayoclinic.org/drug-rash
• American Academy of Dermatology. “Contact dermatitis.” 2022. https://www.aad.org/public/diseases/a-z/contact-dermatitis
• CDC. “Stevens-Johnson syndrome and toxic epidermal necrolysis.” 2021. https://www.cdc.gov/stevens-johnson
• National Institutes of Health (NIH). “Drug hypersensitivity reactions.” 2022. https://www.ncbi.nlm.nih.gov/books/NBK459455/
• Cleveland Clinic. “Topical Steroids for Skin Rashes.” 2023. https://my.clevelandclinic.org/health/drugs/20561-topical-steroids
• World Health Organization. “Pharmacovigilance: the detection of adverse drug reactions.” 2020. https://www.who.int/medicines/areas/quality_safety/pharmacovigilance/en/

```